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MEDICAL PROGRESS 
LIVER TRANSPLANTATION 
(First of Two Parts) 
THOMAS E. STARZL, M.D., PH.D., ANTHONY J. DEMETRIS, M.D., AND DAVID VAN THIEL, M.D. 
ADVANCES in the management of both chronic 
fi and acute hepatic disease have been made possi-
ble and even mandated by the development of liver 
transplantation. The clinical use of transplantation 
has proceeded at a rapid pace since a Consensus De-
velopment Conference of the National Institutes of 
Health concluded inJune 1983 that liver transplanta-
tion had become a service and not simply an experi-
mental procedure. ' 
The liver can be transplanted as an extra (auxiliary) 
organ at an ectopic site, or in the orthotopic location 
after the removal of the host liver (Fig. I). This article 
will focus primarily on the orthotopic procedure. 
However, there has been renewed interest in the auxil-
iary operation, which will be discussed separately. 
CANDIDACY FOR TRANSPLANTATION 
The conceptual appeal of liver transplantation is so 
great that the procedure may come to mind as a last 
resort for virtually every patient with lethal hepatic 
disease. The selection of appropriate recipients from 
such a large pool requires strict individual assessment. 
A 1982 estimate of the annual need for liver transplan-
tation was 15 per million population,2 but the current 
need is undoubtedly higher because there are now few-
er restrictions on candidacy. Between 4000 and 50,000 
liver transplantations a year may be needed in the 
United States. 
The supply of organs will increasingly influence the 
criteria for candidacy and limit the use of the proce-
dure. Discussions about rationing transplantation 
services for this reason are nonetheless premature, be-
cause the balance between need and supply has not 
been determined. In the United States, the yearly rate 
of liver transplantation has reached approximately 
1600; it averaged 147 a month between July and De-
From the Departments of Surgery (T.E.S.). Pathology (A.J .D.), and Medicine 
(D.V.T.), University Health Center of Pittsburgh, University of Pittsburgh, and 
the Veterans Administration Medical Center, Pittsburgh. Address reprint requests 
to Dr. Stanl at the Departmen! of Surgery, Falk Clinic, 3601 Fifth Ave., Pitts· 
burgh, PA 152\3. 
Supported by research grants from the Veterans Administration and a project 
grant (DK 29961) from the National Institutes of Health. 
cember 1988 (Vaughn W, United Network of Organ 
Sharing: personal communication). The annual rate 
in Europe approaches this figure. 
Policies on organ donation will have to be reexam-
ined if substantial growth is to occur. Many potential 
liver donors are probably rejected unjustifiably. The 
arbitrary upper age limit observed by most programs3 
cannot be justified, because senescence largely spares 
the liver.4 Atherosclerosis of the hepatic arteries is not 
usually found beyond the origin of the celiac axis. 4 
Our own limited experience with livers from donors 
over 50 years old has been encouraging. 
Potential donors of all ages are often excluded be-
cause of poor arterial-blood gas levels, their need for 
inotropic or vasopressor drugs, minor abnormalities 
of liver function, or diseases such as diabetes mellitus. 3 
The results with livers from such donors in both the 
United States5 and Europe6 have been as good as those 
with healthier donors. The use of better techniques of 
preservation,7·9 which allow the safe storage of liver 
grafts for a day instead of the previous six or eight 
hours, should reduce organ wastage, since with this 
extra time, countrywide and worldwide networks of 
organ sharing can be created. 
If there is an adequate organ supply and a way to 
finance transplantation, the medical issues of candi-
dacy are relatively clear. In a patient with nonmalig-
nant end-stage liver disease that will not recur in the 
hepatic graft, there is little debate about the rationale 
for transplantation. Transplantation is more debat-
able if the recurrence of a non-neoplastic disease is 
predictable, The most controversial indication for liv-
er transplantation is for the treatment of hepatic can-
cers. However, none of these applications should be 
arbitrarily excluded from future trials. 
Non-neoplastic Liver Diseases 
By 1982 liver transplantation had been used to treat 
more than 20 benign diseases.2 Since then, the list has 
become so longlO. l5 that it is increasingly reported in 
broad categories, such as cholestatic or parenchymal 
disease '6 (Table 1). It is therefore easy to lose sight of 
the fact that more than 60 distinct diseases have been 
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Table 1. Native Liver Disease in 400 Pediatric and 
858 Adult Recipients of Liver Transplants at the 
University of Pittsburgh, 1981-1988. 
DISFASE 
Parenchymal 
Postnecrotic cirrhosis 
Alcoholic cirrhosis 
Acute liver failure 
Budd-Chiari syndrome 
Congenital hepatic fibrosis 
Cystic fibrosis 
Neonatal hepatitis 
Hepatic trauma 
Cholestatic 
Biliary atresia 
Primary biliary cirrhosis 
Sclerosing cholangitis 
Secondary biliary cirrhosis 
Familial cholestasis 
Inborn errors of metabolism 
Tumors 
Benign 
Primary malignant 
Metastatic 
Total 
No. OF CASES 
522 
348 
76 
54 
18 
9 
6 
8 
3 
544 
217 
186 
100 
25 
16 
114 
78 
10 
60 
8 
1258 
treated with liver transplantation, including 16 in the 
broad category of inborn errors of metabolism and 14 
in the category of cholestatic disease. 
In adults, the most common diagnoses have been 
chronic active hepatitis, cryptogenic cirrhosis, prima-
ry biliary cirrhosis, alcoholic cirrhosis, and inborn er-
rors of metabolism. Half or more of the pediatric 
recipients have had biliary atresia, with inborn meta-
bolic errors a distant second. IO- 13 
A number of diseases in which transplantation 
might have been precluded or strongly discouraged 
5 or 10 years ago are no longer absolute contrain-
dications for the procedure, and some are not even 
questionable. A prime example is alcoholic cirrhosis. 
With multidisciplinary care for substance abuse in 
properly selected cases, the results of transplanta-
tion for Laennac's cirrhosis are as good as those 
for other diseases. 17 Somewhat more controversial is 
transplantation in patients with cirrhosis due to hepa-
titis B virus, because the recurrence of viral infection 
cannot be reliably prevented. However, many such 
patients have benefited from transplantation, and it is 
therefore difficult to make the carrier state an absolute 
contraindication. 
An even more difficult issue is whether patients 
with antibodies to the human immunodeficiency virus 
(HIV) should be excluded from candidacy. Shortly 
after screening tests for this disease became widely 
available in the spring of 1985, HIV infections were 
reported in kidney, heart, and liver recipients. At our 
institution, HIV antibodies were found in the stored 
serum of 18 of 1043 kidney, heart, or liver recipients 
(1.7 percent) treated between 1981 and 1986. 18 The 
incidence of HIV in the liver recipients was 2.6 per-
cent, and in one third the antibodies predated trans-
plantation. Seroconversion after transplantation -
through infection from blood-component therapy or 
(uncommonly) from the donor's liver - made up the 
other two thirds. 18 The rate of seroconversion at our 
institution and others has remained unchanged, de-
spite the use of screening assays for HIV antibodies 
beginning in March 1985. 18,19 
The patients infected with HIV have been available 
for study since their transplantation. We have fol-
lowed 10 children who were six months to 16 years old 
at the time of transplantation for I Y2 to 6 years, with 
only one late death from a complication related to 
the acquired immunodeficiency syndrome (AIDS). 
Among 16 adults, the AIDS-related mortality has 
been 37 percent. Many patients can thus have pro-
longed benefit from liver transplantation in spite of 
positive tests for HIV. How this fact has been used in 
decision making varies with the transplantation cen-
ter. The most commonly accepted policy in the United 
States is to screen all recipients for HIV, but not to 
exclude transplantation solely because of a positive 
test. The screening of potential donors is obligatory at 
all centers. Tests that identify both HIV antigens and 
antibodies may make the screening of recipients as 
well as donors more foolproof than it is now. 
In addition to disease states that at one time would 
have ruled out liver transplantation, inflexible age 
proscriptions have been dropped. An upper age limit 
was eliminated when it was demonstrated that recipi-
ents over 50 have a 5-year survival after transplanta-
tion, similar to that of younger adults.20 At the other 
extreme, liver transplantation in very small infants 
and even newborns has become common, although 
the results are better with older children.21 
Extensive thromboses of the portal, mesenteric, or 
splenic veins, which previously made transplantation 
difficult or impossible, have been eliminated in many 
cases through the use of vein grafts. The vein grafts 
are connected to the superior mesenteric vein and 
brought through the transverse mesocolon anterior to 
the pancreas into the liver hilum for anastomosis to 
the portal vein of the new liver. 22,23 The routine use of 
imaging techniques to measure the size of the liver 
and determine the state of the host vessels helps to 
identify these cases in advance, and appropriate plans 
can be made. 
Scarring from multiple upper-abdominal oper-
ations, once considered a contraindication by many 
transplantation teams, is no longer an overriding de-
terrent in major centers. Earlier splenectomy or por-
tal-systemic shunts cause the greatest concern. Since 
any of these operations can alter the portal vein, it is 
no surprise that the majority of complications of por-
tal-vein reconstruction during transplantation have 
been in patients with earlier shunt operations.24 Meso-
caval and distal splenorenal shunts have been least 
harmful, since they do not involve dissection of the 
portal hilum. The shunt must be closed at the time of 
transplantation for optimal vascularization of the 
graft. 
Should shunting operations ever be recommended 
to treat variceal hemorrhage, given that these proce-
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dures can jeopardize the success of the ultimate step, 
liver transplantation? Probably only rarely, since en-
doscopic sclerosis of the varices is an effective alterna-
tive. In some patients with grade A (good-risk) cirrho-
sis according to Child's system, a distal splenorenal 
anastomosis may be the best way to relieve portal hy-
pertension. However, it is important to emphasize 
that a liver transplantation itself decompresses por-
tal hypertension throughout the capillary bed of 
the healthy new liver. Among patients with variceal 
bleeding who were too sick to be considered for any 
operation other than transplantation, the five-year 
survival after their livers were replaced was far superi-
or to that reported in series of patients at generally 
better risk who underwent shunting operations.25 The 
obvious limitations of the shunt in treating variceal 
bleeding have greatly reduced the frequency of portal 
diversions in Western countries. 
Inborn Errors of Metabolism 
Since the products of hepatic synthesis permanent-
ly retain the metabolic specificity of the donor, pa-
tients with inborn errors of metabolism involving the 
liver can be treated by transplantation of a normal 
liver (Table 2).26-41 The longest follow-up in such a 
patient is more than 18 years. The inborn errors of 
metabolism that result partly or completely from 
known deficiencies of specific liver enzymes or from 
abnormal products of hepatic synthesis (Table 2) 
have been treated with the most predictable results. 
With other, less well understood disorders, the trans-
plantation itself helps clarify the pathogenesis, either 
by correcting the inborn error or, equally illuminat-
ing, by failing to do so. By contrast, in one case a 
coagulation defect present in the donor was conferred 
on the recipient. 42 
In the majority of recipients with errors of metabo-
lism, the inborn error itself had damaged the liver, 
and a conventional indication of liver failure or the 
development of malignant hepatic tumors prompted 
its replacement. The correction of the metabolic error 
was therefore incidental. However, anatomically nor-
mal livers have also been replaced solely to correct 
inborn errors (Table 2). 
Many inborn errors that cannot be corrected by 
liver transplantation can be treated with allogeneic 
bone marrow engraftment.43 Determining which kind 
of transplantation will be effective is crucial, and the 
guidelines for decision making have become increas-
ingly clear.27,43 
Cancer 
Most of the first patients treated with liver trans-
plantation had primary or metastatic hepatic cancers 
that could be removed only by total hepatectomy.44 
Although the rate of recurrence proved to be over-
whelming,45-47 the use of liver transplantation to treat 
cancer is still being investigated by many transplanta-
tion teams, often in combination with adjuvant che-
motherapy or other experimental treatment protocols. 
The percentage of patients with a tumor in large 
transplantation programs ranges from 4 to 34 per-
cent lO- 15,47,48; at our institution it has been about 5 per-
cent (Table I). 
Certain kinds of neoplasms have a better prognosis 
than others. Since the recurrence of the original tumor 
is the most common cause of death after liver trans-
plantation under even the best of circumstances, a 
crucial condition of candidacy involves ruling out the 
possibility that the tumor has spread beyond the liver. 
The uncertain prognosis with transplantation should 
be made clear to patients and their families. 
Patients with liver tumors and normal hepatic func-
tion who are referred for transplantation can often be 
treated instead with major hepatic resections with the 
use of techniques that were developed or refined to 
meet such patients' need for more extensive oper-
ations. Resection if feasible or transplantation if nec-
essary should be done promptly. A quick decision and 
action are even more imperative when a liver cancer is 
found in a patient whose liver is failing because of an 
underlying chronic non-neoplastic disease. 
TIMING OF TRANSPLANTATION 
Liver transplantation once seemed so drastic that it 
was used only as a last resort for benign hepatic dis-
ease. Today, allowing a patient's condition to deterio-
rate to the point at which life-support systems are re-
quired before thinking of the transplantation option is 
unacceptable. However, the speed of deterioration is 
highly variable. 
Fulminant Hepatic Failure 
A diagnosis of fulminant hepatic failure can be 
made when sudden massive necrosis occurs in a for-
merly healthy liver/9,5o but not when a previously un-
recognized chronic disease is exacerbated or acute 
Wilson's disease is present. Before 1982,2 transplanta-
tion's results were not good enough to justify this step, 
because recovery without the procedure occurred in 
5 to 20 percent of cases.49,50 Since then, emergency 
transplantation for fulminant hepatic failure has been 
widely acceptedY-54 The predominant causes have 
been non-A, non-B hepatitis, hepatitis B, and toxic 
hepatitis caused by a variety of agents. 
A decision to replace the liver must often be made 
within a few hours. Systematically assessing the fea-
tures of the liver disease can help to distinguish the 
patients with a good chance of recovery from those 
who will die without transplantation.55,56 The cause of 
the disease may be an important prognostic determi-
nant. 56 Features that predict imminent death include 
relentless progression, grade 3 or 4 encephalopathy, 
severe coagulopathy, rapid shrinkage of the liver as 
documented by imaging, metabolic acidosis, cardio-
vascular instability, and sepsis. When a patient has 
grade 4 encephalopathy and is dependent on mechani-
cal ventilation, it is usually too late. 
If transplantation is performed before these grave 
developments, some livers whose lesions are reversible 
may be replaced unnecessarily. A liver biopsy per-
formed after the coagulopathy has been corrected may 
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Table 2. Inborn Errors of Metabolism Treated with Liver Transplantation. 
CORRECTION OF 
DISEASE 
Alpha,-antitrypsin 
deficiency 
Wilson's disease 
Tryrosinemia 
Type I glycogen 
storage disease 
CA usEJDESCRIPTION 
Structural abnormality of the protease 
inhibitor synthesized in liver 
Abnormal biliary copper excretion, 
decreased copper binding to cerulo-
plasmin, and copper accumulation 
in tissues; autosomal recessive gene 
mapped to chromosome 13 
Fumarylacetoacetate deficiency 
Glucose-6-phosphatase deficiency 
METABOLIC 
DEFECT 
Yes 
Yes 
Nearly 
complete 
Yes 
loNGEST ASSOCIATED 
SURVIVAL LIVER DISEASE STUD), 
13 yr' Cirrhosis Hood et aI., ,. 
Starzl27 
16Y, yr' Cirrhosis Starzl,27 Groth 
et al. 28 
7Y, yr' Cirrhosis, hepatoma Starzl et al. 29 
7 yr' Hepatomegaly, Malatack et al. 30 
fibrosis, 
liver tumors 
Type IV glycogen 
storage disease 
Cystic fibrosis 
Amylo-l ,4-transglucosidase Incompletet 4Y, yr' Cirrhosis Starzl" 
Niemann-Pick 
disease 
Sea blue histio-
cyte syndrome 
Erythropoietic 
protoporphyria 
Crigler-Naljar 
syndrome 
Type I hyper-
oxaluria 
U rca-cycle enzyme 
deficiency 
C-protein deficiency 
Familial hypercho-
lesterolemia 
Hemophilia A 
Hemophilia B 
(branching enzyme) defect 
Unknown; pancellular disease, Not known 
liver often affected 
Sphingomyelinase deficiency, Not known 
sphingomyelin storage 
Unknown; neurovisceral No 
lipochrome storage 
Hepatic ferrochelatase deficiency; pos- Incomplete 
sible overproduction of protopor-
phyrin by erythropoietic tissues 
G1ucuronosyltransferase Yes 
deficiency 
Peroxisomal alanine-glyoxylate Yes 
aminotransferase deficiency 
Ornithine carbamoyltrans- Yes 
ferase deficiency 
Defective C-protein synthesis Yes 
Low-density lipoprotein-receptor Incomplete 
deficiency, overproduction of 
low-density lipoprotein 
Factor VIII deficiency Yes 
Factor IX deficiency Yes 
4Y2 yr' Cirrhosis Mieles et al. 31 
2 yr (died) None Daloze et al.32 
7 yr' Cirrhosis Gartner et al. 33 
I VI yr Cirrhosis Samuel et aI. ,34 
Polson et al. 35 
4yr None Wolff et a1. 3• 
8 mo None Watts et aI., 37 
McDonald et aL 37. 
8 mo' None Starzl: unpub-
lished data 
2Y. yr' None Casella et al.'s 
6 yr' None Bilheimer et aL 3. 
4 yr' Cinbosis, a compliea- Lewis et aL 40 
cation of blood-com-
ponent therapy 
6 mo Cirrhosis, a complica- Merion et aI." 
cation of blood-com-
ponent therapy 
*Patients in University of Colorado-University of Pittsburgh series. Follow-up is reported to January 1989. 
t Amylopectin deposits were found in a heart-biopsy specimen four years after transplantation. 
provide decisive information. If the clotting disorder 
cannot be sufficiently corrected to permit a closed-
needle biopsy, the abdomen can be explored when a 
new liver is available for transplantation; the oper-
ation can be stopped if the histopathological examina-
tion of the open-biopsy specimen is favorable. In spite 
of the pitfalls associated with liver replacement for 
fulminant hepatic failure, current survival rates of 55 
to 75 percent after transplantation51 -54 compare favor-
ably with the most optimistic projections of 20 percent 
for medical management alone. The perioperative 
mortality associated with transplantation has fre-
quently been due to brain-stem herniation during or 
just after the procedure, sometimes despite the contin-
uous monitoring of intracranial pressure. To improve 
results, early referral to transplantation centers, ex-
tremely aggressive evaluation, and an early decision 
for surgical exploration and biopsy with the option of 
immediate transplantation are necessary. 
End-Stage Chronic Disease 
A decision to proceed with transplantation requires 
the participation of the primary physician, who may 
have seen a gradually evolving social and vocational 
invalidism that is not evident on first examination. 
The disability may involve encephalopathic dementia 
and the loss of intellectual capacity, frequent hospital-
izations for other complications of liver failure, the 
inability to function in a domestic environment, and 
arrested growth and development in infants and chil-
dren. These issues of the quality of life loom large for 
most patients long before the truly terminal events of 
chronic hepatic failure occur. Formulas to determine 
candidacy for transplantation on the basis of liver-
function tests have not been helpful because the test 
results vary from disease to disease and even within 
the same disease. Patients with cholestatic disorders 
(such as biliary atresia and primary biliary cirrhosis) 
usually become jaundiced but have well-preserved he-
patic synthetic functions for a long time, whereas pa-
tients with hepatocellular disease may not become 
jaundiced despite profound disturbances in the syn-
thesis of albumin and prothrombin. 
The risks of procrastinating too long before decid-
ing to undertake transplantation have not been de-
fined. In a study in which 12 percent of the candidates 
died while waiting, most of that number had arrived 
at the transplantation center on mechanical ventila-
---~""K"" .... ""----".-,.,, ... "".,.,.",._ .. 
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tion and with gastrointestinal bleeding, a coagula-
tion disorder, the hepatorenal syndrome, aspiration 
pneumonitis, subacute bacterial peritonitis, or other 
end-stage complications. 57 At another center,58 the 
mortality among patients who were considered too 
healthy for the active waiting list was higher than 
that among patients who were immediately accepted 
as candidates. When the severity of the disease 
is underestimated and a catastrophic complication oc-
curs, resuscitation is sometimes successful. However, 
the outlook after subsequent transplantation is dem-
onstrably poorer. 59 
The influence of the stage of the liver disease on 
outcome after transplantation has been studied in 
adult patients with primary biliary cirrhosis.6o,61 In 
the most complete of these investigations, the severity 
of' the disease was defined with the use of a formula 
that included age. serum bilirubin level, serum albu-
min level, prothrombin time, and severity of edema; 
life expectancy was predicted without transplanta-
tion.52 The transplant recipients' actual survival was 
markedly better than predicted.60 However, patients 
with less severe liver disease had a low perioperative 
mortality and a two-year survival of 80 percent, 
whereas those whose conditions had deteriorated 
more seriously before transplantation had a high peri-
operative mortality and a two-year survival of only 55 
percent. 50 Clearly, transplantation should be consid-
ered before the stage of catastrophic complications is 
reached. 
An increasing number of patients with normal liver 
function have had orthotopic transplantation for poly-
cystic disease,63 cystic hygroma,64 and adenomatosis. 
The size of their lesions, the consequent disability, 
and the life-threatening complications of mass lesions 
were the indications for urgent operation. The largest 
of the excised livers weighed 16.5 kg.64 
THE REPLACEMENT PROCEDURE 
The evolution of liver transplantation as a practi-
cal form of treatment has been summarized else-
where. 2,45,65 In orthotopic liver transplantation, the 
diseased organ is removed and replaced with a cadav-
eric liver in the most anatomically normal way possi-
ble (Fig. I). Many methods of dealing with anomalies 
or other features of the donor's or recipient's blood 
vessels have been described.22,23,45,66,,68 
Extracorporeal venovenous-bypass techniques have 
been used in adults since 1983 to decompress the 
splanchnic and systemic venous systems, which arc 
obstructed while the native liver is being removed and 
the homograft inserted.69 The bypass is often too cum-
bersome to use in very small infants, and some sur-
geons omit it in adult patients. 65,70 
The biliary tract can be reconstructed by connect-
ing either the donor's and recipient's common ducts 
end to end over aT-tube stent (inset, Fig. 1)2 or the 
common duct of the homograft to a limb of the je-
junum in a Roux anastomosis (Fig. I). 2,7! There is a 10 
to 15 percent incidence of late bile-duct obstruction, 
which requires correction with interventional radiolo-
Figure 1. Orthotopic Liver Transplantation. 
Biliary reconstruction can be accomplished through choledocho-
jejunostomy or duct-to-duct anastomosis (inset). 
gy, secondary duct reconstruction, or occasionally re-
transplantation. 71 ,.73 In a technique that incorporates 
the donor's gallbladder in a conduit between the 
donor's common duct and the recipient's anastomotic 
site,74 a high incidence of late sludge and stone forma-
tion occurs.75 
Methods of reducing the size of transplants, which 
permit the transplantation of part of a liver, have been 
perfected in recent years in Paris/6 Hanover, West 
Germany,77 and Chicago,78 allowing greater flexibility 
in matching available donors to the needs of recipi-
ents. Pediatric recipients have benefited most. 
PERIOPERATIVE GRAFT FAILURE 
If a graft fails to function, the only recourse is re-
transplantation before cerebral edema and brain-stem 
herniation occur. 79 Lesser degrees of graft injury can 
allow short-term survival, but retransplantation or 
death remains the end point. The rate of retransplan-
tation in the first three postoperative months is 10 to 
20 percent.9,79 There are four general reasons for graft 
failure, which are not mutually exclusive: a technically 
imperfect operation, unrecognized liver disease in the 
donor, an ischemic injury in the graft, and accelerated 
rejection. The least likely is undetected disease in the 
donor, although in a few indisputable cases donors' 
livers have had diffuse fatty infiltration.8o,8! 
Obvious technical complications account for less 
than 10 percent of the primary graft failures in adults 
but 30 percent of those in infants and children. 79 The 
risk in infants is inversely related to the patient's 
size,2! and complications are mainly attributable to 
vascular thrombosis. 2!,82 A multivariate factor analy-
sis of pediatric recipients83 found that the risk of arte-
rial thrombosis increased if the vessels were smaller 
than 3 mm in diameter, if the anastomoses had to be 
revised, or if aortic or iliac grafts were needed as con-
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duits to the hepatic artery. Unsuspected reductions in 
portal venous or hepatic arterial flow can be detected 
with routine electromagnetic flow monitoring. 84 
Portal-vein thrombosis is rare and usually occurs 
only when the recipient's splanchnic venous bed has 
been altered by a portal-systemic shunt, a splenecto-
my, or another operation. 24 Venous thrombi can be 
carried to the recipient through the portal vein of the 
~i~er graft, particularly if the donor has had a splenic 
lllJury. 
Iatrogenic problems, such as the overzealous cor-
rection of clotting defects83,85 and polycythemia 
caused by overtransfusion,86 can contribute to the 
thrombosis of a hepatic artery or portal vein. Defi-
ciencies in protein C and antithrombin and defective 
fibrinolysis have been described in children.87 Injury 
to the hepatic microvasculature caused by ischemia 
and refrigeration,88 cyclosporine-induced changes in 
the prostanoid metabolism and other homeostatic 
processes of vascular endothelial cells,8Y and reduc-
tions in hepatic blood flow due to rejection9o,91 may be 
other nontechnical factors. 
When thrombosis occurs in the hepatic artery, it 
may be asymptomatic in 20 to 30 percent of cases,82,92 
and the diagnosis can only be made with the routine 
use of Doppler ultrasonography.93 However, the com-
plications that can result are serious, and they include 
failure of the primary graft to function, septic hepatic 
infarction of part of the liver, bacteremia, abscess, the 
rupture of the dearterialized ducts with bile peritonitis 
or bile leakage, and the formation of biloma within the 
graft parenchyma. 4),65,68,82,92,94 Later, multiple intrahe-
patic biliary strictures that resemble sclerosing cho-
langitis may form.72,Y'1.95 Although secondary rearteri-
alization has been attempted, retransplantation is 
usually the only recourse. 
Early portal-vein thrombosis usually requires re-
transplantation,24 but a few patients have been saved 
by immediate or delayed secondary reconstruction of 
the portal vein. 2 Two patients in whose reconstructed 
portal veins thrombosis occurred had distal spleno-
renal shunts to treat portal hypertension. 96,97 
The most common cause of postoperative graft dys-
function is ischemic injury incurred during the death 
of the donor, the procurement operation, or the period 
of refrigeration. In controlled experiments in animals, 
the degree of damage to the liver graft was related to 
the length of time it was refrigerated. 98 This associ-
ation is far less clear in a clinical setting,9 particularly 
when an improved preservation solution developed at 
the University of Wisconsin is used. This solution, 
which is infused through the portal vein or hepatic 
artery, allows the safe cold storage of canine and hu-
man livers for at least 24 hours and possibly longer. 7-9 
It has a number of cryoprotective ingredients, and its 
effectiveness has been explained as a result of their 
cumulative action. 
Intracellular pH, energy charge, mitochondrial 
function, and the level of free-radical scavengers in 
preserved liver tissue do not accurately predict graft 
quality in laboratory animals. The ATP content of the 
preserved graft falls sharply, even during the initial 
chilling infusion. In laboratory animals, it is the rapid-
ity with which levels of ATP can be restored after 
revascularization rather than its level under storage 
that is a useful prognostic sign. Consequently, the 
measurement of ATP levels during preservation has 
not been considered helpful as a prospective indicator, 
except in a single clinical report.99 
Once the liver has been revascularized, the produc-
tion of bile is the most important predictor of suc-
cess.2,65 In humans, there is an almost perfect correla-
tion between the production of bile, the rapidity with 
which A TP levels in the liver are restored after revas-
cularization, and survival. 100 Next to the production of 
bile, the restoration of clotting function85 and the ab-
sence of lactic acidosis 101,102 are the best predictors of 
success. The coagulopathy that occurs during the 
transplantation procedure is characterized by fibrinol-
ysis, the deficiency of specific clotting factors and 
platelets, and the consumption of the clotting compo-
nents. 44,8) Standard liver-function tests during the 
days that follow almost always verify the accuracy of 
the simple assessments of bile production and clotting 
made during the operation. Measurements of blood 
amino acid clearance and other products of interme-
diary metabolism have been used to distinguish be-
tween patients whose new livers are and are not ex-
pected to recover. 101 ,J02 
If other explanations for primary failure to function 
or dysfunction have been eliminated, host immune 
factors may be responsible. No unequivocal examples 
of the kind of hyperacute rejection that can immedi-
ately destroy human kidneys and hearts have been 
reported,103 and this supports the widely held opin-
ion 104 that the liver is resistant to such antibody-
mediated injury. Because of this resistance, liver 
transplantation is often performed in spite of major-
blood-group incompatibilities l05 that because of the 
antigraft specificities of the isoagglutinins would pre-
clude renal or cardiac transplantation. l03 However, 
the risk of rejection is increased. 10,>-lo8 Isoagglutinin 
fixation has been demonstrated in the microvascula-
ture of major blood group-incompatible liver grafts in 
a collection of cases in which hemorrhagic infarction 
occurred five times more frequently than in patients 
with compatible grafts. 107 The loss of the liver graft 
proceeded more slowly than a hyperacute rejection of 
kidneys, but the result was the same. 
The role of cytotoxic antilymphocyte antibodies in 
the failure of liver grafts has been less well delineated. 
These antibodies, which have antigraft specificity in 
kidney recipients, are highly predictive of hyperacute 
rejection 109: the microvasculature of the renal graft is 
occluded by rapidly sequestered blood elements and 
clotting factors. 103,lIo If the process is not promptly 
completed, a consumptive coagulopathy, fibrinolysis, 
or both can develop. III 
Hyperacute rejection of the liver was suspected in 
one of the first clinical attempts at orthotopic liver 
transplantation. llz A child's graft developed hemor-
rhagic necrosis a few hours after the operation in a 
--K----~--
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manner similar to that described many years later in 
rats l13 and in Rhesus monkeys I 14 sensitized with skin 
homografts before orthotopic liver transplantation. 
However, other experiments in animals have demon-
strated the liver's special protection from humoral re-
jection. ll :; 
The liver's resistance to cytotoxic antibodies is so 
strong that a positive cytotoxic crossmatch does not 
preclude transplantation. 103,104 At the same time, it is 
becoming evident that accelerated (possibly humoral) 
rejection of liver grafts can OCCUr.1l6.118 The process 
develops more slowly than in the kidney and presum-
ably other organs, may be reversible, and is not 
strongly associated with the antigraft antibodies that 
are measured in standard blood typing. I 16 A progres-
sive and severe coagulopathy that develops shortly 
after hepatic revascularization should arouse suspi-
cion of an accelerated rejection, even without a posi-
tive cytotoxic crossmatch.1I6 The prompt destruction 
of second transplants in patients whose first liver 
grafts were lost for unclear reasons has been reported 
by several centers. I 16 
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MEDICAL PROGRESS 
LIVER TRANSPLANTATION 
(Second of Two Parts) 
THOMAS E. STARZL, M.D., PH.D., ANTHONY J. DEMETRIS, M.D., AND DAVID VAN THIEL, M.D. 
REJECTION AND HISTOCOMPATIBIUTY 
Although the possibility of rejection is always pres-
ent, nonimmunologic causes of early hepatic dysfunc-
tion must be ruled out systematically. The differential 
diagnosis can include suboptimal revascularization; 
defects in biliary reconstruction that cause obstruction 
or bile fistula; opportunistic infection with cytomeg-
alovirus, 119,120 herpes simplex viruses,12O Epstein-Barr 
virus, or adenovirus 121 ; infection by various bacterial 
or fungal pathogens122; toxicity caused by hyperali-
mentation or sepsis 123; and hepatotoxicity of the drugs 
used to prevent rejection.45,124 Later graft dysfunction 
can be caused by a recurrence of the disease that de-
stroyed the native liver, infection of the transplant by 
a hepatitis virus, defects in the reconstruction of the 
bile duct, or chronic rejection. Needle biopsies of the 
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liver can provide some of the most important evidence 
for or against rejection.80.123.125.129 
It has been suggested that the liver is less suscep-
tible to rejection than other organs, because perma-
nent or prolonged acceptance of a graft has been 
achieved relatively easily in dogs after a three- or four-
month course of immunosuppression45, 130 and because 
pigs frequently have long survival with no treatment 
at all. 131 However, in humans the advantage, if it 
exists at all, is only nominal; histopathologic evidence 
of rejection can be found after two thirds or more of 
clinical transplantations. 125,132.134 
The principal features of acute cell-mediated rejec-
tion in dogs and other species 126 are mononuclear-cell 
infiltration (which is heavily concentrated in the por-
tal triads), edema, and parenchymal necrosis. The 
bile ducts, veins, and arteries appear to be most com-
monly damaged. 
Acute cellular rejection causes various degrees of 
cholestatic jaundice, failure of hepatic synthetic proc-
esses, and elevations in the levels of enzymes that de-
note liver necrosis or injury.45 Lymphocytosisl 35 and 
eosinophilia136 can also occur, but they are not consis-
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tently present or specific. Measuring levels of interleu-
kin-2 receptors may be useful. m 
Another kind of rejection has been called chronic 
rejection because it usually evolvt"s insidiously and 
cannot be reversed with intt"nsified therapy. Frequent-
ly, hepatic synthetic functions are well preserved 
while obstructive jaundice develops.4s.138 Cellular 
infiltration mav be minimal. The identifying patho-
logic characteristics are the presence of occlusive 
arterial lesions similar to those found in other kinds 
of organ grafts, the destruction of the small intra-
hepatic bile ducts, and fibrosis, which occasionally 
evolves into cirrhosis.45.123.126.127 Paradoxically, these 
"chronic" features can develop within a few weeks 
after transplantation. 138 Some observers have noted an 
increased incidence of chronic rt"jection. especially 
the disappearance of small bile ducts, in patients 
who had lymphocytotoxic antibodies before their op-
erationsl39.14o or bouts of cytomegalovirus hepatitis.141 
Drastic changes in the expression of Class I and 
Class II major histocompatibility antigens by liv-
er parenchymal and vascular endothelial cells have 
been reported in human hepatic allografts during 
rejection as well as in grafts damaged by ischemia, 
duct obstruction, hepatitis, and other adverse con-
ditions.142·147 Functional analyses of the T lympho-
cytes invading a graft during rejection have suggested 
that early acute cellular rejection is associated with a 
Class I-specific infiltrate, whereas later episodes and 
chronic rejection are associated with Class II allo-
reactive cells. 148 Although these observations may be 
relevant to an understanding of pathogenic mech-
anisms, none of the patterns appear to be entire-
ly specific or clinically useful. Dendritic cells that 
are normally present in the portal tracts of the 
liver as "passenger leukocytes" are potent stimula-
tors of the mixed-lymphocyte reaction and may have 
a key role in localizing the inflammation in rejec-
tion. 142,149.15o Later, the obliterative lesions that devel-
op in the intraparenchymal hepatic arteries can con-
tribute to the loss of small bile ducts and to strictures 
in large ducts, since the ducts depend on the supply of 
arterial blood. 149,150 
I t is not clear whether the extent of matching of the 
Class I and Class II antigens has a major effect on 
these pathologic and clinical events. An inverse rela-
tion has been described between the extent of match-
ing and the outcome. 140,141,151 Although hypotheses 
have been advanced to explain these unexpected find-
ings, further observation is needed before any conclu-
sions can be reached. 
Another unexplained phenomenon is a transplanted 
liver's protective effect on other tissues and organs 
transplanted at the same time or later from a single 
donor. It has recently been shown that Class I anti-
gens of donor specificity appear in the plasma of liver 
recipients less than 24 hours after transplantation and 
that these soluble, circulating antigens persist in large 
quantities for the life of the liver graft. 152 The recipi-
ent's original histocompatibility antigens did not dis-
appear from the plasma, proving that the Ji\'Cr is not 
their only source. The continued presence of soluble 
donor antigens may help explain the liver graft's abili-
ty to reduce humoral antibody titers and to shield a 
kidney from the same donor from the hyperacute re-
jection that a positive cytotoxic-antibodv crossmatch 
would ordinarily foreshadow. J 51 K upffer cells may also 
have a role in protecting the liver from humoral rejec-
tion. The nontoxic absorption of immunoglobulins by 
sinusoidal non parenchymal cells (probably Kupfier 
cells) of liver grafts has been documented in sensi-
tized rats. 154 
The liver's protective effect against cell-mediated 
rejection of the skin, heart, and kidney was first noted 
in pigs 155 and studied extensively in rats. 1';0 The lack of 
an effective cellular immune reaction against donor 
organs after liver grafting in animals may be due to 
the presence of enhancing or protective antibodies, 
the clonal deletion or sequestration of cells capable 
of causing rejection, and increased suppressor-cell ac-
tivity.156 
Not all immunologic reactions after liver transplan-
tation involve rejection. Graft-versus-host disease has 
been reported in patients given livers whose major 
blood groups were compatible but not identical to 
their own (for example, a liver from a type-O donor 
given to a type-A recipient).157 A donor's lymphoid 
tissue, carried with the liver,126.158 apparently pro-
duced antihost red-cell isoagglutinins, which caused 
hemolysis. In addition, graft-versus-host disease in-
cluding a skin rash has been reported in a recipient 
whose own tissue contained monocytes from the 
donor.159 Increased immunosuppression relieves these 
syndromes. 
PREVENTING REJECTION 
Liver transplantation was a passive follower of kid-
ney transplantation in the development of immuno-
suppressive techniques. 2 Today, cyclosporine is the 
most commonly used maintenance drug,160 and ste-
roids are almost invariably added to it. 161 Azathio-
prine may be used as a third agent to reduce the dose 
of cyclosporine, 133,162 and in some cases it has replaced 
cyclosporine altogether after a few months or later. 
Antilymphocyte-globulin preparations,133 including 
the monoclonal antibody OKT3, 163,164 have been giv-
en prophylactically and for the specific indication of 
rejection. OKT3 reacts against all mature T lympho-
cytes. Many of the polyclonal antilymphocyte globu-
lins l33 affect B lymphocytes as well. 
The liver's ability to regenerate and to regulate its 
size is important after transplantation, when recovery 
from ischemic injury or rejection is usually necessary. 
In addition, the transplanted liver promptly adjusts 
its volume, shrinking or growing to reach a size appro-
priate to the recipienLl65.166 Some drugs, such as doxo-
rubicin, that patients undergoing liver replacement for 
hepatic tumors may take are known to inhibit regen-
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eration.167.168 In contrast, cyclosporine actually en-
hances regeneration after partial hepatectomy.169.171 
This hepatotrophic effect resembles that of insulin in 
non transplantation models. l72 
The development of cyclosporine has been the sin-
gle most important factor in making liver transplan-
tation practical. The history of the field is usually 
described in terms of the eras before and after cyclo-
sporine (Fig. 2). However, even when cyclosporine is 
used in multidrug regimens, rejection remains a com-
mon cause of early and, especially, late graft losses. 2.79 
Cyclosporine's principal side effect, nephrotoxici-
ty,160,161,173 limits the permissible dose. In human re-
cipients of livers and hearts, evidence of renal dys-
function has included azotemia, hyperkalemia, and 
hypertension. Because the morphologic changes in the 
kidneys of these patients may not be reversible,174.17h 
the eventual cost of short- or long-term cyclosporine 
therapy has yet to be determined. 
Nephrotoxicity can be limited if renal function 
is used as the principal guide in determining the dose 
of cyclosporine, as it was 161,177 before blood lev-
els of the drug could be measured. Even today, there 
is much to be said for this approach. Because the 
therapeutic ranges of cyclosporine trough levels 
vary with different methods of measurement,178 each 
transplantation center usually develops its own stand-
ards based on observed toxicity and the frequency of 
rejection, The desirable blood or plasma trough level 
varies with a number of factors, among them the pa-
tient, the use of other drugs, the time after trans-
plantation, 179 the changing quality of graft function, 180 
the presence of bile-duct obstruction or T-tube drain-
age,181 and the existence of bile fistulas, 182,183 
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Figure 2, Survival of 170 Liver-Transplant Recipients Treated be-
fore Cyclosporine Became Available (1963-1979), as Compared 
with the Survival of 1258 ReCipients Treated between 
1980 and Mid·1988. 
The patients were treated by a Single team at the University of 
Colorado through 1980 and at the University of Pittsburgh there-
after, The solid line denotes patients receiving azathioprine 
(n = 170), and the broken line those receiving cyclosporine 
(n = 1258). Survival is calculated with use 
of the life-table method, 
Without new drugs, further improvements in the 
management of rejection will probably be minor. A 
promising agent called FK 506, which was described 
in 1987184.185 and tested extensively in rats, dogs, mon-
keys, and baboons,184.187 is undergoing its first clinical 
trials in liver and kidney recipients with encouraging 
results (unpublished data). 
The balance between immunosuppression and sus-
ceptibility to infectious diseases is more delicate in 
liver recipients than in heart and kidney recipients, 
because the hepatic graft is directly exposed to the 
microorganisms of the intestinal tract. 45 ,122,133.188·190 
Animal studies have shown that a liver graft damaged 
by ischemia or rejection becomes a sieve through 
which bacteria pass. 191 Tissue barriers must be main-
tained intact while the patient is undergoing potent 
immunosuppressive treatment in order to prevent this 
"leakage" of bacteria. 45 Patients have been treated be-
fore transplantation with oral antibiotics that suppress 
pathogenic gram-negative organisms and fungi but al-
low anaerobes to survive in a process of selective intes-
tinal decontamination. 192 The morbidity, but not the 
mortality, from postoperative infection has been re-
duced. In addition to its unproved value, selective de-
contamination has practical limits: a cadaveric liver 
may not be available when the results of antibiotic 
treatment reach their peak. 
Much remains to be learned about the subtle rela-
tions between host defenses and invasive bacteria in 
liver transplantation. The recipient's macrophage sys-
tem, of which the liver is an important component, 193 
is profoundly altered by transplantation. Within a 
short time after the operation, all of the Kupffer 
cells in the graft are replaced with host macro-
phages,126,143,194 whereas the hepatocytes and vascular 
endothelial cells remain specific to the donor. 126 The 
dysfunction or absence of Kupffer cells may cause or 
contribute to the wave of endotoxemia that occurs in 
dogs during the anhepatic phase of the operation and 
afterward. 195 The increased level of endotoxin may 
also be responsible for serious perioperative complica-
tions in humans. 196 
Viral infections occur at some point after trans-
plantation in the majority of liver recipients. 119,122,19i 
Cytomegalovirus is the most common cause of post-
operative hepatitis. 119,197 Protection against serious 
cytomegalovirus infection has been reported with 
hyperimmune globulin. 198 Patients generally recover if 
immunosuppressive treatment is reduced and espe-
cially if they are treated with ganciciovir. 199 However, 
strains of cytomegalovirus that are resistant to ganci-
clovir have recently been reported. 20D Hepatitis caused 
by adenovirus l21 or herpesviruses 123 is uncommon, but 
because hepatic necrosis can result, immunosuppres-
sive treatment should be stopped temporarily when 
such infections are diagnosed. 
After the transplantation of any organ, primary in-
fection with the Epstein-Barr virus or its reactivation 
can produce conditions ranging from an infectious 
mononucleosis syndrome (as seen in the general popu-
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lation) to life-threatening Iymphoproliferative disease. 
Lymphoproliferative tumors (B-ceIl Ivmphomas) have 
been found most frequen til' in liver recipients20l.202 -
especially infants and children, in whom the risk dur-
ing the first two years after transplantation may be as 
high as IO percent. 2(J2 The liver graft itself is often 
involved. If immunosuppressive treatment is re-
duced20l.202 and acyclovir therapv addeeVU3 many (but 
not all) of the lymphomas will regress without rejec-
tion of the graft.201.202 
RECURRENCE OF NATIVE DISEASE 
Hepatic Cancer 
Small incidental cancers usually do not recur, but 
larger cancers of all cell types generally metasta-
size.lo.45-48.204 Death has been caused by their recur-
rence as early as 3 months after transplantation, but 
the highest mortality occurs between 6 and 36 months 
(Fig. 3). In addition to tumor size, cell type and 
the presence of hilar-Iymph-node metastases or un-
derlying liver diseas(' influence results.2.l5.4ti .. lH.lo4 Hep-
atocellular carcinomas - except the fibrolamellar 
variane·46,47.204.2O'i - almost always recur.46 Duct-cell 
carcinomas, even the small Klatskin's tumors that are 
located high in the hepatic hilum, almost alwavs re-
cur,46,47.204 although they did not in a recent German 
study.48 In more than half the reported patients with 
epithelioid hemangioendotheliomas, survival for at 
least two years has been achieved.47.206 
In the dismal record of transplantation in patients 
with primary hepatic tumors, there has been little or 
no emphasis on adjuvant therapy. Immunomodula-
tion and chemotherapy are now being attempted for 
the first time_ Even a few patients with metastatic liver 
disease have benefited from liver transplantation (Fig. 
3),10.11,204,207.208 particularly if their primary tumors 
were neuroendocrine.IO·204.208 In one case, a patient 
with multifocal liver metastases from a carcinoma of 
the breast had prolonged palliation with chemothera-
py, autotransplantation of the bone marrow, and liver 
transplantation,207 although recurrences ultimately 
developed (Margreiter R: personal communication, 
August 1986). 
Hepatitis B 
Removing the diseased liver reduces the titer of 
hepatitis B, as measured by the level of surface anti-
gen in the blood,209,210 but with rare exceptions212-21S 
the graft becomes infected despite passive immuno-
prophylaxis. 1s,210'2l:l Viral immunity has been demon-
strated in patients with fulminant hepatitis,210,211 but 
in most of those with chronic aggressive hepatitis, the 
recurrence of the disease in the graft jeopardizes re-
covery209.210,213 and substantially reduces long-term 
survival (Fig. 4). Coinfection with the delta virus is a 
confounding factor that recurs with the hepatitis B 
infection. 
Efforts to treat hepatitis B carriers peri operatively 
with hyperimmune globulin or interferon alfa have 
failed. 210,211,213,215 However, a human monoclonal anti-
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Figure 3. Survival after Liver Transplantation of 60 Patients Treat-
ed for Primary Hepatic or Bile-Duct Cancers and 8 Patients Treat-
ed for Metastatic Liver Cancer as Compared with That of 1190 
Patients Treated for Benign Liver Disease. 
Patients are from the University of Pittsburgh series, from the 
period (1980-1988) during which cyclosporine was available. The 
solid line denotes patients with benign liver disease, the broken 
line those with primary tumors. and the dotted line those with 
metastatic tumors. Survival is calculated with use 
of the life-table method. 
body directed against hepatitis B has been produced 
(Sandoz, East Hanover, ~KgKF by fusing peripheral-
blood lymphocytes from an immune man with cells of 
a mouse X human myeloma-cellline. 216 The resulting 
human monoclonal hyperimmune globulin is 50,000 
times more potent than commercially available hyper-
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Figure 4. Influence on Survival of the Hepatitis 8-Carrier State. 
Survival is compared in 51 adult patients with chronic active hepa-
titis (broken line) who underwent transplantation between 1983 
and 1988 (before 1983 positivity for hepatitis B surface antigen 
was considered a contraindication), in 332 contemporaneous pa-
tients without cancer (dotted line) who had post-necrotic cirrhosis 
from other causes (cryptogenic, hepatitis B immune. non-A, non-
B hepatitis, autoimmune. alcoholic, or drug related), and in 412 
contemporaneously treated adults (solid line) with other benign 
causes of end-stage liver disease (mostly chOlestatic). Survival is 
calculated with use of the life-table method. Patients are from the 
University of Pittsburgh series. 
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immune globulin prepared from the blood of immune 
donors. This monoclonal antibody has been given to a 
few patients after liver transplantation.217 with incon-
clusive results. Further trials have been slowed by a 
shortage of the antibody. 
Non-A, Non-B Hepatitis 
The recurrence of non-A. non-B hepatitis has been 
documented tentativelym.2lH but not often. Since this 
low incidence of recu~rence may reflect merely the 
difficulty of establishing the diagnosis, the recent de-
scription of a specific non-A, non-B marker called 
"hepatitis C" may clarify the issue. 21 'l Bone marrow 
aplasia, which can also complicate milder attacks of 
non-A, non-B hepatitis that do not require liver trans-
plantation, has been observed in children a few days 
or weeks after their livers have been replaced.22u.221 
Four of the nine who had bone marrow aplasia sur-
vived, usually with a slow recovery of the hematopoi-
etic system. 221 
Other Recurrent Diseases 
The recurrence of the Budd-Chiari svndrome211.222 
can be prevented with anticoagulants. 222-n + An initial 
report of the recurrence of primary biliary cirrhosis22 '> 
has not been confirmed in a larger series,226 although 
the antimitochondrial antibodies found in this dis-
order either do not disappear after transplantation or 
reappear after a transient disappearance.226.227 A syn-
drome resembling sclerosing cholangitis has been re-
ported in a liver homograft,22H but the same diagnosis 
has been made after transplantation in patients who 
did not have biliary tract disease.123 There has been 
one report of recurrent autoimmune hepatitis.229 
TRANSPLANTATION OF MORE THAN ONE ORGAN 
There have been many reports of the transplanta-
tion of the liver and a kidney; the liver and pancreas, 
liver and heart, and liver, heart, and lung are less 
frequent combinations. In these cases, the organs were 
transplanted separately, so two standard procedures 
were performed in the same patient. 
The liver has also been transplanted as part of vis-
ceral organ clusters, which included the pancreas and 
the entire gastrointestinal tract in two children with 
the short-gut syndrome and hepatic failure.23o.231 
Maximal survival was six months.23o In 10 adults the 
liver, along with the pancreas, duodenum, and proxi-
mal jejunum, were transplanted to replace upper-
abdominal organs removed because of tumors.232 
Eight of these recipients are alive after 4 to 10 months 
without evidence of recurrence. 
QUALITY OF LIFE 
In the early days of liver transplantation, the qual-
ity of life was both defined and predicted by the liver-
function profile after a year of convalescence and 
the quantity of steroids needed to maintain that lev-
el of function. 233 Cyclosporine has minimized the 
need for steroids. Several studies have shown the re-
markably restored physical and emotional well-being 
that can be expected in infants and children,23:l·23+ in-
cluding resumed growth and even catch-up growth.23, 
In adult liver recipients studied before and two 
years after surgery, social interaction, home manage-
ment, alertness, the use of recreational and leisure 
time, and overall psychosocial functioning improved 
broadly 236 The severity of the stress experienced 
by patients and their spouses after transplantation 
correlated closelv with the ease of recoverv. Over 
90 percent of the patients who undergo ~ single 
transplantation say that they have no problems or 
only minor health problems two years later. More 
than 85 percent return to work and say that they are 
able to perform their jobs well. In contrast, the smaller 
number of survivors who have undergone more than 
one transplantation have a much poorer outcome; be-
cause of one or more disabilities, only 43 percent are 
able to work. 
Patients treated in the period during which cyclo-
sporine has been available have only been followed 
since 1980. However, a bellwether group of survi-
vors remains from an original series of 170 patients 
treated between 1963 and 1979.237 Twenty-eight of 
these recipients are alive after 10 to 19 years. They 
represent exactly half the survivors after one year. 
Only two patients who were alive after five years have 
since died. One of the late deaths was caused by 
chronic rejection after l2Y2 years. The other was 
from a lymphoma 13Y2 years after transplantation. 
Rehabilitation has been complete in the long-term 
survivors. 237 
AUXILIARY TRANSPLANTATION 
In auxiliary transplantation, an extra liver is placed 
in the right paravertebral gutter, rearterialized from 
convenient adjacent vessels, and provided with a por-
tal-venous inflow from the recipient's portal or superi-
or mesenteric vein. Splanchnic-venous inflow is criti-
cal to optimal graft function,238 because this blood 
contains so-called hepatotrophic factors, of which in-
sulin is the most important. 239.240 In almost all clinical 
trials, which by 1978 numbered more than 50, a 
splanchnic-venous inflow to the auxiliary graft was 
provided.241 
An auxiliary transplantation that truly prolonged 
life was first achieved in 1972.241 The recipient, who 
had biliary atresia, is still alive more than 16 years 
later (Fortner JG: personal communication, April 
1989). In 1980, the 29-month survival of an adult re-
cipient was reported from Paris.242 The patient, who 
had hepatitis B, died of a hepatocellular carcinoma in 
his native liver eight years after transplantation (Bis-
muth H: personal communication, January 1989). 
As orthotopic liver transplantation became increas-
ingly successful, interest in auxiliary transplanta-
tion waned. However, the transplantation of whole 
livers or liver fragments to the right paravertebral 
gutter of six adult recipients in essentially the same 
operation as that used in the past has recently been 
reported. 243 At the time of the report, all six re-
cipients were alive and had been followed for 5 to 
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23 months. 243 The reports of cautious further trials 
will undoubtedly be forthcoming. 
FINANCIAL SUPPORT AND PUBUC ApPEALS 
The ability to pay for liver transplantation has a 
profound influence on candidacy. Ironically, the feasi-
bility and then the practicality of transplantation wert" 
established before a way to finance it was considered. 
In 1983, a planning commission for the Common-
wealth of Massachusetts estimated that the average 
cost of liver transplantation would be $238,800 in the 
first year,244 although the actual costs were only a third 
of this amount in a large, existing program. 245 It is 
clear that the bill can be astronomical if a patient is 
severely disabled by the time of transplantation, if the 
first liver graft does not function well, and if serious 
complications develop and perhaps require a second 
transplant. 24.7 
Because of their fear of runaway expenses, many 
health insurance carriers and government agencies 
have avoided financial responsibility by classifying liv-
er transplantation as experimental,246 despite the Con-
sensus Development Conference's conclusion to the 
contrary.' An answer to cost-conscious funding agen-
cies has been that liver transplantation can eliminate 
the repeated and expensive hospitalization of patients 
who are slowly dying of chronic hepatic disease.247-249 
Liver transplantation in the United States has been 
paid for by a heterogeneous system of private health 
insurance programs, government agencies, and public 
and private fund-raising activities. One highly visible 
consequence has been the recurrent spectacle of fam-
ilies and patients pleading on television and in the 
press for economic help or an organ donor. Mean-
while, statistics accrue showing that blacks and pre-
sumably other minorities are grossly underrepresent-
ed among liver-transplant recipients.25o Developing a 
system that allows all citizens equal and reasonable 
access but avoids the extraordinary expense of past 
programs, such as the federally financed End Stage 
Renal Disease Program, may require new and creative 
administrative approaches. 
Before anything can be achieved, more information 
about the true cost of liver transplantation is desper-
ately needed. It is puzzling that no formal study has 
been published since 1983. It would be reasonable to 
expect a reduction in expenses as large numbers of 
patients are treated in the major transplantation cen-
ters, but evidence for this is entirely anecdotal. The 
next step in the evolution of liver transplantation may 
depend on a scholarly assessment of its fiscal impact 
on hospitals and the society that supports them. 
We are indebted to Ms. Terry Mangan for help in the planning, 
research, editing, and typing of this manuscript. 
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